[
  {
    "ts": null,
    "headline": "5 Large Cap Drug Stocks: Values or Traps?",
    "summary": "Some drug stocks are cheap but is it another fake out?",
    "url": "https://finnhub.io/api/news?id=6b37ae979ad1261a96d773275c84229ccfdaabe06d40dae948855552f983204c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759524900,
      "headline": "5 Large Cap Drug Stocks: Values or Traps?",
      "id": 136980576,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Some drug stocks are cheap but is it another fake out?",
      "url": "https://finnhub.io/api/news?id=6b37ae979ad1261a96d773275c84229ccfdaabe06d40dae948855552f983204c"
    }
  },
  {
    "ts": null,
    "headline": "B of A Securities Maintains AbbVie (ABBV) Neutral Recommendation",
    "summary": "B of A Securities Maintains AbbVie (ABBV) Neutral Recommendation",
    "url": "https://finnhub.io/api/news?id=44ff87600122174ac1e96af288978f237847faf422962440e7e8ecdf335aa786",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759510401,
      "headline": "B of A Securities Maintains AbbVie (ABBV) Neutral Recommendation",
      "id": 136966046,
      "image": "",
      "related": "ABBV",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=44ff87600122174ac1e96af288978f237847faf422962440e7e8ecdf335aa786"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock underperforms Friday when compared to competitors",
    "summary": "AbbVie Inc. stock underperforms Friday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=ca42f444cdd28c213a0690bb485d4d55600a82a861a4373907a86a1da365957f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759509060,
      "headline": "AbbVie Inc. stock underperforms Friday when compared to competitors",
      "id": 136995799,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock underperforms Friday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=ca42f444cdd28c213a0690bb485d4d55600a82a861a4373907a86a1da365957f"
    }
  },
  {
    "ts": null,
    "headline": "Is PFE Stock a Buy After 14% Rise Post Drug Pricing Deal With Trump?",
    "summary": "Pfizer surges 14% after landmark Trump deal slashing drug prices while boosting U.S. investments.",
    "url": "https://finnhub.io/api/news?id=efa23a72bc7c155f7e813fa90c5b87573487e3e25ce5bc0f38399ad887aff7a9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759499940,
      "headline": "Is PFE Stock a Buy After 14% Rise Post Drug Pricing Deal With Trump?",
      "id": 136980580,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Pfizer surges 14% after landmark Trump deal slashing drug prices while boosting U.S. investments.",
      "url": "https://finnhub.io/api/news?id=efa23a72bc7c155f7e813fa90c5b87573487e3e25ce5bc0f38399ad887aff7a9"
    }
  },
  {
    "ts": null,
    "headline": "How BeOne Medicines, An IBD 50 Stock, Is Taking On Big Names In Cancer Treatment",
    "summary": "As the former BeiGene gears up to battle AbbVie and J&J, shares of the new BeOne Medicines haven't been this high in four years.",
    "url": "https://finnhub.io/api/news?id=542f2b1b75b8988cf9ad4aa311e83a32204312a65c8d207c95eda8dff57335b3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759492844,
      "headline": "How BeOne Medicines, An IBD 50 Stock, Is Taking On Big Names In Cancer Treatment",
      "id": 136963844,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "As the former BeiGene gears up to battle AbbVie and J&J, shares of the new BeOne Medicines haven't been this high in four years.",
      "url": "https://finnhub.io/api/news?id=542f2b1b75b8988cf9ad4aa311e83a32204312a65c8d207c95eda8dff57335b3"
    }
  },
  {
    "ts": null,
    "headline": "Does AbbVie's (ABBV) Manufacturing Expansion Signal a Shift in Its Long-Term Growth Focus?",
    "summary": "AbbVie recently submitted a Biologics License Application to the FDA for its investigational cancer therapy pivekimab sunirine and announced a US$70 million expansion of its Bioresearch Center in Massachusetts to enhance biologics manufacturing for immunology and oncology medicines. These moves highlight AbbVie's ongoing focus on strengthening its oncology pipeline and scaling domestic production in response to growing demand and policy incentives for US-based pharmaceutical...",
    "url": "https://finnhub.io/api/news?id=f50e07e4f4b518cd12ead878088f7e7af21bdd35832a18953626b7ab3823171d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759491894,
      "headline": "Does AbbVie's (ABBV) Manufacturing Expansion Signal a Shift in Its Long-Term Growth Focus?",
      "id": 136964308,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie recently submitted a Biologics License Application to the FDA for its investigational cancer therapy pivekimab sunirine and announced a US$70 million expansion of its Bioresearch Center in Massachusetts to enhance biologics manufacturing for immunology and oncology medicines. These moves highlight AbbVie's ongoing focus on strengthening its oncology pipeline and scaling domestic production in response to growing demand and policy incentives for US-based pharmaceutical...",
      "url": "https://finnhub.io/api/news?id=f50e07e4f4b518cd12ead878088f7e7af21bdd35832a18953626b7ab3823171d"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: Wins Accumulating While We Wait For Next BD Steps",
    "summary": "AbbVie's strong results, pipeline wins, and Rinvoq exclusivity boost its outlook. Read the latest analysis on ABBV stock here.",
    "url": "https://finnhub.io/api/news?id=df50562df1cd4b9c1b3c819916262a60ade92b76019fd75f8d05f4fb3a90cae6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759489533,
      "headline": "AbbVie: Wins Accumulating While We Wait For Next BD Steps",
      "id": 136964952,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/912015590/image_912015590.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AbbVie's strong results, pipeline wins, and Rinvoq exclusivity boost its outlook. Read the latest analysis on ABBV stock here.",
      "url": "https://finnhub.io/api/news?id=df50562df1cd4b9c1b3c819916262a60ade92b76019fd75f8d05f4fb3a90cae6"
    }
  },
  {
    "ts": null,
    "headline": "Bernstein Remains a Hold on AbbVie Inc. (ABBV)",
    "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best medical stocks to buy now. In a report released on September 25, Courtney Breen from Bernstein maintained a Hold rating on AbbVie Inc. (NYSE:ABBV) without assigning a price target. AbbVie Inc. (NYSE:ABBV) reported in its fiscal Q2 2025 earnings that the diluted EPS for the quarter reached […]",
    "url": "https://finnhub.io/api/news?id=abdbdb7a013c63ce19e68c6c99d95040e73243abba6b9cff017f7c263c5589fb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759487275,
      "headline": "Bernstein Remains a Hold on AbbVie Inc. (ABBV)",
      "id": 136963187,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best medical stocks to buy now. In a report released on September 25, Courtney Breen from Bernstein maintained a Hold rating on AbbVie Inc. (NYSE:ABBV) without assigning a price target. AbbVie Inc. (NYSE:ABBV) reported in its fiscal Q2 2025 earnings that the diluted EPS for the quarter reached […]",
      "url": "https://finnhub.io/api/news?id=abdbdb7a013c63ce19e68c6c99d95040e73243abba6b9cff017f7c263c5589fb"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb, Takeda, Astex Join AI Consortium to Train OpenFold3 for Accelerated Drug Discovery",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the most undervalued stocks to buy and hold for 5 years. On October 1, Bristol-Myers Squibb, Takeda Pharmaceuticals (NYSE:TAK), and Astex Pharmaceuticals agreed to collaborate and pool proprietary data for drug discovery using an AI model. These companies are joining an existing consortium that already includes AbbVie Inc. […]",
    "url": "https://finnhub.io/api/news?id=7d4864be8561163f177ed8bce88625ff4dcdd85c5c7ff67f53b7d4b96cb712e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759483994,
      "headline": "Bristol-Myers Squibb, Takeda, Astex Join AI Consortium to Train OpenFold3 for Accelerated Drug Discovery",
      "id": 136963179,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the most undervalued stocks to buy and hold for 5 years. On October 1, Bristol-Myers Squibb, Takeda Pharmaceuticals (NYSE:TAK), and Astex Pharmaceuticals agreed to collaborate and pool proprietary data for drug discovery using an AI model. These companies are joining an existing consortium that already includes AbbVie Inc. […]",
      "url": "https://finnhub.io/api/news?id=7d4864be8561163f177ed8bce88625ff4dcdd85c5c7ff67f53b7d4b96cb712e4"
    }
  },
  {
    "ts": null,
    "headline": "2 Healthcare Stocks to Research Further and 1 Facing Challenges",
    "summary": "Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This has capped returns as the industry’s six-month gain of 6.5% has lagged the S&P 500’s 24.7% climb.",
    "url": "https://finnhub.io/api/news?id=393a3ecd1a0d4aeea151a0e8a50e1adb0056c3ce1be4f94dec169cc520812539",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759466298,
      "headline": "2 Healthcare Stocks to Research Further and 1 Facing Challenges",
      "id": 136963189,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This has capped returns as the industry’s six-month gain of 6.5% has lagged the S&P 500’s 24.7% climb.",
      "url": "https://finnhub.io/api/news?id=393a3ecd1a0d4aeea151a0e8a50e1adb0056c3ce1be4f94dec169cc520812539"
    }
  }
]